NAMS 8-K: press release and investor presentation furnished

Rhea-AI Filing Summary

NewAmsterdam Pharma (NAMS) furnished an update on November 5, 2025, announcing corporate updates and financial results for the quarter ended September 30, 2025. The company also posted an updated corporate investor presentation on its website.

Both the press release and the investor presentation were furnished as Exhibits 99.1 and 99.2, respectively, and are not deemed filed under the Exchange Act or incorporated by reference, except as expressly stated in future filings.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000193625800-00000000001936258us-gaap:CommonStockMember2025-11-052025-11-050001936258us-gaap:WarrantMember2025-11-052025-11-0500019362582025-11-052025-11-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2025

NewAmsterdam Pharma Company N.V.

(Exact name of Registrant as Specified in Its Charter)

The Netherlands			001-41562	N/A
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
Goomieer 2-35
Naarden
The Netherlands				1411 DC
(Address of Principal Executive Offices)				(Zip Code)
			+31 (0) 35 206 2971
(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary shares, nominal value €0.12 per share		NAMS		The Nasdaq Stock Market LLC
Warrants to purchase ordinary shares		NAMSW		The Nasdaq Stock Market LLC

☐	Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
☐	If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On November 5, 2025, NewAmsterdam Pharma Company N.V. (the “Company”) issued a press release announcing corporate updates and its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

On November 5, 2025, the Company posted an updated corporate investor presentation on its website (https://www.newamsterdampharma.com). A copy of the corporate investor presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. The information contained on, or that can be accessed from, the Company’s website is not incorporated into, and does not constitute a part of, this Current Report on Form 8-K.

** The information contained in Item 2.02 and Item 7.01, including Exhibit 99.1 and Exhibit 99.2, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). Additionally, the information contained in Item 2.02 and Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		NewAmsterdam Pharma Company N.V. Press Release, dated November 5, 2025
99.2		NewAmsterdam Pharma Company N.V. Corporate Presentation, dated November 5, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NewAmsterdam Pharma Company N.V.
Date:	November 5, 2025	By:	/s/ Ian Somaiya
		Name:	Ian Somaiya
		Title:	Chief Financial Officer

FAQ

What did NewAmsterdam Pharma (NAMS) announce in this 8-K?

The company furnished a press release with corporate updates and financial results for the quarter ended September 30, 2025, and an updated investor presentation.

Which exhibits were included with NAMS’s 8-K filing?

Exhibit 99.1 is the press release dated November 5, 2025; Exhibit 99.2 is the corporate presentation dated November 5, 2025.

Are the furnished materials considered filed with the SEC?

No. The information in Items 2.02 and 7.01, including Exhibits 99.1 and 99.2, is furnished and not deemed filed under the Exchange Act.

What period do the financial results cover for NAMS?

The results cover the quarter ended September 30, 2025.

Where are NAMS’s securities listed and under what symbols?

Ordinary shares trade on Nasdaq as NAMS and warrants trade as NAMSW.

Did the 8-K include an investor presentation?

Yes. An updated corporate investor presentation was posted and furnished as Exhibit 99.2.